Summit Therapeutics Inc. (SMMT)

業務介紹

峰會治療公司是一家生物製藥公司,在美國和拉丁美洲發現、開發和商業化用於治療傳染性疾病的藥物。該公司專注於進行針對克羅斯特里迪艾菌感染(CDI)的臨床計劃。該公司的主要產品候選藥物是ridinilazole,這是一種口服小分子抗生素,正處於III期臨床試驗階段,用於治療CDI。該公司還提供SMT-738,用於對抗多重耐藥感染,主要是碳青黴烯耐藥腸桿菌感染;以及DDS-04系列,用於潛在治療由腸桿菌科引起的感染。該公司成立於2003年,總部位於麻薩諸塞州劍橋。



Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

公司網址

https://www.summittxinc.com